Amneal Q3 2022 revenue $546M (+3.2% YoY), adj. EBITDA $126M, adj. EPS $0.14

Amneal Pharmaceuticals, Inc.

2022-Q3 EPS reported -$0.83 revenue$1,602,545,000

Net revenue $546M, up 3.2% from $529M in Q3 2021; GAAP net loss $3M (diluted EPS $(0.02)).
Adjusted EBITDA $126M, down 5.1% YoY; adjusted diluted EPS $0.14 vs $0.21 in prior year.
Full-year 2022 outlook maintained; management cites new product approvals and biosimilar launch momentum.
AvKARE delivered double-digit growth; Generics and Specialty segments remained consistent.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Amneal Pharmaceuticals, Inc. reported the third quarter ended September 30, 2022 results: revenue $546 million, net income $3 million, EPS $(0.02). Guidance reaffirmed.

Period: the third quarter ended September 30, 2022
Revenue: $546 million
Net income: $3 million
EPS: $(0.02)
Guidance: reaffirmed
Result: reported results

Exact text from the filing

the information furnished pursuant to Item 2.02 of this report. --- EX-99.1 (EX-99.1) --- AMNEAL REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS ‒ Q3 2022 Net Revenue of $546 million; GAAP Net Loss of $3 million; Diluted Loss per Share of $(0.02) ‒ ‒ Adjusted EBITDA (1) of $126 million; Adjusted Diluted EPS (1) of $0.14 ‒ ‒ Maintaining 2022 Full Year Outlook

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Amneal Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001723128-22-000037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.